Analysts predict that Myovant Sciences Ltd (NYSE:MYOV) will post ($0.42) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Myovant Sciences’ earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.39). Myovant Sciences reported earnings per share of ($0.15) in the same quarter last year, which suggests a negative year-over-year growth rate of 180%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Myovant Sciences will report full-year earnings of ($1.74) per share for the current financial year, with EPS estimates ranging from ($1.79) to ($1.68). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.95) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Myovant Sciences.

Several analysts have recently issued reports on MYOV shares. Zacks Investment Research cut Myovant Sciences from a “hold” rating to a “sell” rating in a report on Friday, November 17th. JMP Securities reaffirmed an “outperform” rating and set a $25.00 price objective (up from $23.00) on shares of Myovant Sciences in a report on Wednesday, October 4th. Robert W. Baird reaffirmed a “buy” rating and set a $20.00 price objective on shares of Myovant Sciences in a report on Friday, November 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $22.50.

Myovant Sciences (NYSE MYOV) traded up $0.07 during midday trading on Wednesday, reaching $12.43. The company had a trading volume of 85,800 shares, compared to its average volume of 55,105. Myovant Sciences has a one year low of $9.92 and a one year high of $18.85. The stock has a market cap of $753.83, a PE ratio of -8.82 and a beta of -2.42.

Several institutional investors and hedge funds have recently modified their holdings of MYOV. Goldman Sachs Group Inc. purchased a new stake in shares of Myovant Sciences during the 2nd quarter worth approximately $174,000. Swiss National Bank bought a new position in shares of Myovant Sciences during the 2nd quarter valued at approximately $294,000. OxFORD Asset Management LLP increased its position in shares of Myovant Sciences by 15.4% during the 2nd quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after purchasing an additional 3,971 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Myovant Sciences during the 2nd quarter valued at approximately $648,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Myovant Sciences during the 3rd quarter valued at approximately $1,255,000. 79.21% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://theolympiareport.com/2017/12/27/0-42-earnings-per-share-expected-for-myovant-sciences-ltd-myov-this-quarter.html.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.